Concentrations of Ustekinumab During Induction Therapy Associate With Remission in Patients With Crohn’s Disease-Reference-Cited by-同舟云学术

Concentrations of Ustekinumab During Induction Therapy Associate With Remission in Patients With Crohn’s Disease

Published:2019-11 Issue:12 Volume:17 Page:2610-2612
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Soufflet Ninon,Boschetti Gilles,Roblin Xavier,Cuercq Charlotte,Williet Nicolas,Charlois Anne-Laure,Duclaux-Loras Remi,Danion Pauline,Mialon Anne,Faure Mathias,Paul Stéphane,Flourie Bernard,Nancey Stéphane^ORCID

Funder

Centre Lyonnais d'Enseignement et de Recherche en Gastroentérologie

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference8 articles.

1. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease;Sandborn;N Engl J Med,2012

2. Ustekinumab as induction and maintenance therapy for Crohn’s disease;Feagan;N Engl J Med,2016

3. Efficacy and safety of dose adjustment and delayed response to ustekinumab in moderate-severe Crohn’s disease patients: results from IM-UNITI maintenance study;Sands;Gut,2017

4. Association between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn’s disease;Battat;Clin Gastroenterol Hepatol,2017

5. Pharmacokinetics and exposure response relationships of ustekinumab in patients with Crohn’s disease;Adedokun;Gastroenterology,2018

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Approach to loss of response to advanced therapies in inflammatory bowel disease;World Journal of Gastroenterology;2024-06-14

2. Baseline Assessment of Serum Cytokines Predicts Clinical and Endoscopic Response to Ustekinumab in Patients With Crohn’s Disease: A Prospective Pilot Study;Inflammatory Bowel Diseases;2024-06-12

3. Postoperative Ustekinumab Drug Levels and Disease Activity in Patients with Crohn’s Disease;Digestive Diseases and Sciences;2024-05-24

4. Therapeutic drug monitoring in patients with inflammatory bowel disease on ustekinumab;Journal of Digestive Diseases;2024-04

5. Association between Ustekinumab Trough Levels, Serum IL-22, and Oncostatin M Levels and Clinical and Biochemical Outcomes in Patients with Crohn’s Disease;Journal of Clinical Medicine;2024-03-07